Detailed Narrative
Q1 FY26 Performance Overview: Standalone Dip vs. Consolidated Strength
Hester Biosciences reported a mixed Q1 FY26. Standalone divisional product-wise performance stood at INR63 crores, reflecting a 14% degrowth, with standalone PAT declining by 7%. This was primarily due to timing delays in institutional orders in the India business. However, on a consolidated level, divisional sales increased, and PAT grew by over 100%, driven by strong international performance and effective margin control.
Animal Health Division Faces Headwinds
The Animal Health division, encompassing Ruminant and Petcare businesses, experienced a significant 33% decline in revenue. This decline was attributed to the deferred execution of two major immunization programs for PPR and lumpy skin disease. These programs are tender-driven, leading to non-linear timelines. Management anticipates a return to traction in this segment in Q2.
Poultry Healthcare Shows Marginal Growth and New Product Traction
The Poultry Healthcare division recorded a marginal growth of 2%, supported by sustained demand for key vaccines like Newcastle disease and Marek's. Feed supplements and disinfectants, launched last year, are gaining market acceptance, and their contributions are expected to improve further over the next two quarters. The company is actively working to gain more market share in this segment.
Hester Africa Achieves Significant Turnaround
Hester Africa demonstrated a remarkable turnaround, moving from a loss in the prior year's same quarter to a profit of INR5 crores this quarter. Its top line surged from INR3 crores to INR17 crores, marking a substantial increase. This improvement was driven by enhanced commercial execution and better market penetration, with the Tanzania facility now stabilized and serving as a base for regional expansion.
Strategic Initiatives and Product Pipeline Updates
The company is advancing its product pipeline, with preparations underway for the launch of the avian influenza vaccine, awaiting regulatory clearances expected this quarter. The BSL-3 facility, representing INR176 crores in work-in-progress as of March 2025, is being repurposed for animal vaccine production, with governmental permission anticipated in the next few months. Hester is also actively engaging with African agencies regarding PPR vaccine tenders and exploring opportunities for an African swine fever vaccine.
Optimistic Outlook for Remaining FY26
Management expressed optimism for the remainder of FY26, expecting institutional demand to normalize and increased momentum in newer markets for both Petcare and Poultry portfolios. They are confident in returning to overall growth in the coming quarters, emphasizing continued focus on capacity utilization, improving logistics, and growing local engagement, particularly in the strategic African market.